大行評級|大摩:重申康方生物為首選 依沃西單抗III期臨牀達主要研究終點
摩根士丹利發表報吿指,康方生物依沃西單抗III期臨牀達至主要研究終點,相信股價反應正面,並預期在世界肺癌大會上完整數據公佈將推動股價進一步上升。雖然公司最近在美國臨牀腫瘤學會(ASCO)披露的AK112另一個適應症數據後導致股價大幅下跌,但該行認為今次積極的更新應該會恢復投資者的信心,並推動股價回升到ASCO公佈前的水平。該行重申康方生物是其覆蓋中首選的生物技術公司,給予評級“增持”,目標價64港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.